Filing Flows › Neogenomics (NEO) › Client direct billing revenue
Neogenomics (NEO) Client direct billing revenue by quarter
Neogenomics' Client direct billing revenue was $136M in Q3 2026 (third quarter 2026), -2% from Q2 2026. Over the last 7 quarters it ranged from $122M (Q1 2025) to $138M (Q2 2026).
| Quarter | Client direct billing revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $136M | -2% | +2% |
| Q2 2026 | $138M | +5% | +5% |
| Q1 2026 | $132M | -1% | +8% |
| Q4 2025 | $133M | +0.8% | — |
| Q3 2025 | $132M | +0.9% | — |
| Q2 2025 | $131M | +7% | — |
| Q1 2025 | $122M | — | — |
Q3 2026 at a glance
Neogenomics, Q3 2026: revenue $209M (+11% year over year), operating margin -3.8%, net loss $7.5M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Neogenomics' Client direct billing revenue?
Neogenomics' Client direct billing revenue was $136M in Q3 2026 (third quarter 2026), -2% from Q2 2026.
How has Neogenomics' Client direct billing revenue changed?
Over the last 7 quarters it ranged from $122M (Q1 2025) to $138M (Q2 2026).